Metabolism: Efficacy and safety of dipeptide peptidease 4 inhibitors in the treatment of type 2 diabetes

In the treatment guidelines for type 2diabetes, it is recommended that dipeptide peptide enzyme 4 inhibitors (DPP-4is), which are part of the enterotic gneudelogen drug, be used as a second- or third-line therapyCompared with other sugar-lowering drugs, they have good drug tolerance and safetyrecently published a study in the journal Metabolism-Clinical and The Authes, a leading journal for metabolic diseases, which discussed data on the use of DPP-4is and itscardiovascular, and compared safety and efficacy with other oral anti-sugar drugsThe review incorporates currently available original research, abstracts, commentary articles, systematic evaluations, and meta-analysisDPP4is single drug therapy can effectively reduce HbA1c level by 0.5%, and combined with other drugs can reduce by 1.0%Compared with other sugar-lowering drugs, they have good tolerance and safetyHowever, there may be a risk associated with acute pancreatitis andpancreatic cancerto date, cardiovascular outcome trials have shown cardiovascular safety for ischemic events in patients treated with ceratin, sagretin, agretin, linalistin, and VidalettinStudies have shown that data on increased hospitalization rates for patients treated with sagretin do not appear to be an effect of drug categories